CVS Health Stock Is Beating the Market in 2026. Here's Why Wall Street Thinks It Can Soar Another 22%.

CVS Health, a prominent pharmacy chain, has seen its shares soar over 18% year-to-date, outpacing the S&P 500's sub-13% increase. Analysts project the stock could rise another 22% to reach $114.59 per share. The company has consistently beaten analyst estimates for revenue and profitability in each of its three quarterly reports this year, with adjusted net income of $2.57 per share in Q1 and $2.58 in Q2.

The healthcare benefits segment, which includes insurer Aetna, has played a significant role in CVS's success, with its medical benefit ratio (MBR) dropping in Q1 and then improving to 87.4% by the end of Q2. UBS analyst Kevin Caliendo raised his price target to $126 per share, maintaining a buy recommendation despite challenges facing the company's CVS Caremark pharmacy benefits manager.

Despite not being included in The Motley Fool's 10 best stocks for investors to buy now, many analysts view CVS Health as a promising long-term investment.